|
COPYRIGHT 2004 International Medical News Group
(bevacizumab, Genentech)
A recombinant monoclonal antibody that inhibits angiogenesis, for use in combination with 5-fluorouracil (5-FU) as a first-line treatment for metastatic colorectal cancer. This is the first angiogenesis inhibitor approved for any indication, and the "first such product that has been proven to delay tumor growth ... and...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
